AZ's Alexion Acquisition Looks Astute Bit Of Business
Offers $39bn For Rare Disease Drug Pioneer
Executive Summary
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.
You may also be interested in...
BioCryst Halts Trials For BCX9930 Due To Safety Concerns
Biotech stops enrollment in three Phase II studies of oral Factor D inhibitor BCX9930 after seeing elevated creatinine levels. The halt is voluntary, and enrolled patients can continue dosing, BioCryst says.
AstraZeneca Clears Ultomiris Overhang With Patent Settlement
The company will pay Chugai $775m to settle a patent dispute related to the complement 5 inhibitor Ultomiris, which it acquired from Alexion.
AstraZeneca Stays Hopeful About Ultomiris Despite Initial Conversion Difficulties
AstraZeneca is touting Ultomiris’ future potential in neurological conditions as it struggles to convert patients from predecessor Soliris in one of its indications.